Important note: Information in this article was accurate in 2003. The state of the art may have changed since the publication date.
|
|
United Press International - February 12, 2003
Peggy Peck, UPI Science News
Six months of treatment with the drug called PegIntron not only reduced active human immunodeficiency virus but also boosted the immune system, said Dr. Norbert H. Brockmeyer of Ruhr University, Bochum, Germany. The viral load, a measure of HIV activity, dropped by more than 800 percent while CD-4 cells, a measure of the body's immune system activity, increased by 30 percent.
He presented the results at the 10th Conference on Retroviruses and Opportunistic Infections in Boston.
PegIntron, or pegylated interferon Alfa-2b as it is known medically, was a major breakthrough for treatment of hepatitis C because it allows for once-a-week treatment rather than daily injections of interferon. Interferon is a difficult drug to tolerate because often it causes severe headaches, flu-like illness, fatigue and depression in patients. PegIntron has these same side effects but the once a week dosing cuts down on the frequency.
Brockmeyer studied 10 patients with early stage HIV. All patients had no symptoms and had not yet received treatment for the virus. At baseline, Brockmeyer tested the patients' blood to determine both CD-4 count and viral load.
Five patients, all men, were assigned to weekly PegIntron injections while the other five patients -- two women and three men -- received no treatment.
At baseline the average CD-4 count in the group that received PegIntron was 462 while the average baseline CD-4 count in the control group was 535. After six months, the average CD-4 count in the treatment group had increased to 611 while the average CD-4 in the control group had dropped to 450.
The differences in viral loads -- a term that refers to the amount of viral genetic material circulating in the blood -- dropped form 22,158 copies/ml to 3,039 copies/ml. At the same time the viral load in the control group patients went from 7,136 copies/ml to 40,092 copies.
Moreover, there were no serious side-effects in the treatment group, a finding many researchers found surprising.
Dr. Robert Schooley of the University of Colorado Health Center in Denver, who was not associated with the study, said most interferon studies report a higher rate of side-effects.
"This is a little surprising," he said, but noted the ease of treatment may be from the low dose used by Brockmeyer. The dose was about half of the standard PegIntron dose.
Brockmeyer said the results were so impressive his group is now conducting a larger study that combines the drug with standard HIV antiretroviral treatment. Schooley said several other researchers have similar pegylated interferon studies underway.
The study was funded by the German Competence Network HIV/AIDS Ministry of Sciences.
030212
UP030203
Copyright © 2003 - United Press International. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through United Press International, Permissions Desk, 1510 H St. N.W. Washington DC 2005. Main Phone Switchboard: 202-898-8000 FAX: 202-898-8057 or 202-898-8147 Email: info@upi.com.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Elton John AIDS Foundation UK, the National Library of Medicine, AIDS Walk of Orange County, and donations from users like you.
Always watch for outdated information. This article first appeared in 2003. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2003. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .